Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, has announced the launch of ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai. This new platform introduces an autonomous 'Computational Biologist' agent designed to perform end-to-end bioinformatics and multi-omic analysis across various cancer types. Initially available through an early-access program for select academic, industry, and company collaborators, ZetaOmics aims to automate complex research workflows while embedding domain-specific intelligence to improve analytical rigor and reproducibility.
According to the company, ZetaOmics combines 14 specialized tools that can autonomously design, execute, and validate biological analyses. It can detect potential flaws in experimental design and generate publication-quality results with a complete audit trail. Lantern Pharma stated that the platform expands withZeta.ai's commercial opportunity beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers, and contract research organizations through subscription-based offerings and strategic collaborations.
The launch of ZetaOmics represents a significant step in Lantern Pharma's strategy to leverage artificial intelligence in drug development. The company's proprietary RADR platform and pipeline include LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
With the introduction of ZetaOmics, withZeta.ai becomes commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. Lantern Pharma operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
For more details, the full press release is available at https://ibn.fm/9sIIl. Additional updates and news about Lantern Pharma can be found in the company's newsroom at https://ibn.fm/LTRN.
